Reduction of Unnecessary Biopsies

Almost 2% of screening mammograms result in biopsy, and approximately 70% of these biopsies are benign (Taplin, 2010).  In fact, $4 billion is spent annually in the U.S. on mammography false positives (Ong, 2015), however, mammography is the only screening study shown in randomized clinical trials to decrease breast cancer mortality.   

CureMetrix is working to demonstrate the dramatic potential of our proprietary algorithm’s ability to vastly reduce unnecessary biopsies.  In a recent study of 734 biopsy benign cases, CureMetrix cmAssist™ software was able to correctly classify 70% of the biopsies as benign.  These cases are the hardest for a radiologist as demonstrated by a 100% false positive rate on the benign cases.  Had the radiologist utilized cmAssist during the screening, they may have reconsidered recalling the patient to biopsy a lesion that was not marked suspicious by cmAssist.  Ultimately, decreasing the unnecessary biopsies is more cost effective for the hospital and decreases patient anxiety about breast cancer screening.  Studies show that false-positive findings on screening mammography cause long-term psychosocial harm to the patient (Brodersen, 2013).

Incorrect biopsy of a microcalcification correctly classified as verifiably benign by cmAssist™